DigniCap™ Scalp-Cooling System Featured at New Spire Healthcare Opening

~ Latest Therapy to Prevent Chemotherapy-Related Hair Loss Offered at Montefiore Hospital ~

LONDON (November 21, 2012)-On Wednesday, November 21st, The Montefiore Hospital, a new hospital for Brighton and Hove, opened its doors, offering patients a modern and attractive hospital facility conveniently situated in the heart of the city. Among the superb range of private hospital services available at Montefiore is the DigniCap Scalp-Cooling system, one of the most innovative and scientifically-advanced treatments available for reducing chemotherapy-related hair loss in men and women. The DigniCap system, developed by Dignitana, a world leader in scalp-cooling technology, is a safe, gentle and effective treatment for avoiding hair loss related to chemotherapy.

Clinical results show that eight out of ten women in Europe and Asia who used the DigniCap cap system during chemotherapy retained their hair.  Additional trials at leading medical centers around the world have proven the system to be a viable alternative for both women and men of diverse ethnicities. Further clinical results from investigations of the efficacy of scalp cooling with the DigniCap system in both the U.S. and the U.K. will be presented at medical conferences and in publications throughout 2013. 

 "For many cancer patients, the thought of hair loss is emotionally devastating," said Martin Waleij, CEO Dignitana. "The trusted cancer specialists at Spire Healthcare's new Montefiore Hospital know that healing involves both mind and body. We are honored that Montefiore which is the second SPIRE clinic to invest in our system has joined the growing list of top hospitals around the world that include the DigniCap system in their comprehensive approach to cancer care."

For more information about the DigniCap scalp-cooling system offered at Brighton's new Montefiore Hospital please email montefiore@spirehealthcare.com

Media Contacts:

US, UK and International , Scandinavia

Caren Browning, Martin Waleij, CEO,Dignitana  

The Morris + King Company , + 46 733 93 70 76              

00 1 212 617464, martin.waleij@dignitana.se

Caren.browning@morris-king.com                                      

About Spire Healthcare
Spire Healthcare is the second largest private hospital provider in the UK, with 37 hospitals and ten clinics nationwide. The company is built on a heritage of almost 30 years' experience running successful private hospitals and offers a full range of integrated surgical, medical and diagnostic services.

For more information visit http://www.spirehealthcare.com.

About Dignitana AB (publ)
Dignitana AB, a Swedish medical device company, listed on the OMX Nasdaq First North Stockholm, focused  on the patented invention DigniCap™ system , a medical device for preventing hair-loss in chemotherapy patients and for technologies within the area of medical cooling.

For more information visit www.dignitana.com

Dignitana installs the first DigniCap Delta Scalp Cooling System in Rome

Dignitana ABmanufacturer of The DigniCap® Scalp Cooling System, has announced installation of the first DigniCap Delta at the prestigious Gemelli University Hospital in Rome, Italy last month.


Dignitana Promotes Scalp Cooling at Supportive Care Conference

Dignitana ABworld leader in clinically superior scalp cooling technology, is co-sponsoring a scalp cooling session at the Multinational Association for Supportive Care in Cancer (MASCC) Annual Meeting, held June 21 - 23 in San Francisco, California.


Kommuniké från Dignitana AB årsstämma 2019

Dignitana AB, tillverkare av Dignicap®scalp Cooling system, höll idag årsstämma i bolagets lokaler på traktorgränden 3 i Lund. Stämman beslutade i enlighet med samtliga förslag som styrelsen och aktieägare lagt fram. Nedan följer en sammanfattning av de beslut som fattats. 


Communication from the Dignitana AB Annual General Meeting 2019

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, has today held an Annual General Meeting at the company's premises at Traktorgränden 3 in Lund. In all the proposed cases, the AGM resolved in accordance with the Board's proposal. Below is a summary of the decisions taken. 


Dignitana AB Publishes Q1 2019 Interim Report

Results and financial position

Significant events during the period

  • Sales and other income for the period amounted to 10,106 TSEK, $1,102 KUSD, an increase of 69 percent compared to the same period in 2018 and a15 percent quarter over quarter growth compared to fourth quarter 2018.
  • EBITDA amounted to (2,799) TSEK, ($305) KUSD, a 59 percent improvement compared to the same period in 2018.
  • Contracts were signed for 22 locations globally, bringing the total number of sites in the U.S. to 125 in 29 states at the close of first quarter.
  • Dignitana announced receipt of CE Marking approval for European sales of the new DigniCap Delta device.
  • As a result of the rights and directed equity issues in December, Dignitana now has 48,599,155 shares registered at Swedish Companies Registration Office.
  • Dignitana announced a partnership with oneservice GmbH, a global provider of specialty technical services, to provide service and maintenance to facilities offering DigniCap in Europe.

Dignitana Leadership Efforts Prompt Landmark Legislation

Dignitana AB (publ)manufacturer of The DigniCap® Scalp Cooling System, announces that HB3984, the bill providing coverage for scalp cooling that the company initiated in February with Texas State legislators, was passed in the Texas House of Representatives on Friday. The Bill now moves to the Senate where it will be introduced by Sen. Angela Paxton. Once passed in the Senate, the Bill then requires approval by Texas Governor Greg Abbott before being signed into law.


Kallelse till årsstämma i Dignitana AB (publ)

Aktieägarna i Dignitana AB (publ), 556730-5346("Bolaget") kallas härmed till årsstämma onsdag den 15 maj 2019 kl. 9.00 i Bolagets lokaler, Traktorgränden 3, i Lund.


Notice of Annual General Meeting of Dignitana AB (publ)

Aktieägarna i Dignitana AB (publ), 556730-5346("Bolaget") kallas härmed till årsstämma onsdag den 15 maj 2019 kl. 9.00 i Bolagets lokaler, Traktorgränden 3, i Lund.


Rättelse: Felaktig MAR-klassificering i tidigare pressmeddelande

Dignitana AB issues a rättelse i pressmeddelande "Dignitana AB publicerar årsredovisningen för 2018." Rättelsen avser att pressmeddelandet var felaktigt klassat som MAR och innehöll därför stycket som följer:


Correction: Incorrect MAR Classification in previous press release

Dignitana AB issues a correction in press release "Dignitana AB publishes the annual report for 2018." The correction means that the press release was incorrectly classified as MAR and therefore contained the paragraph as follows:


Dignitana AB publicerar årsredovisningen för 2018

Lund, Sweden - 12 April 2019 - Dignitana AB offentliggör härmed årsredovisningen avseende 2018. Årsredovisningen finns som bilaga till detta pressmeddelande samt går att ladda ner från hemsidan, www.dignitana.se. Det går även att beställa en utskriven version via investorrelations@dignitana.com.


Dignitana AB Publishes Annual Report for 2018

Lund, Sweden - 12 April 2019 - Dignitana AB hereby publishes the annual report for 2018. The Annual Report is attached to this press release and will be posted today on the Dignitana website. You can also order a printed version via investorrelations@dignitana.com.


Dignitana AB Receives CE Marking for Next Generation DigniCap Delta to Reduce Hair Loss from Chemotherapy

Dignitana AB (publ), manufacturer of The DigniCap® Scalp Cooling System, today announced receiving CE Marking approval for European sales of DigniCap Delta, the next generation scalp cooling device. An advanced and redesigned model of the 2015 FDA-cleared DigniCap Scalp Cooling System, DigniCap Delta features a new single patient use cap system consisting of a flexible Cooling Wrap and an adjustable Thermal Cap to optimize scalp cooling outcomes and ease-of-use for patients and nurses. The streamlined DigniCap Delta is 54 percent smaller than the current model and the intuitive interface provides up to 80 percent reduction in nursing time per patient infusion versus the existing device.


Dignitana CEO William Cronin to Speak at Aktiedagen Stockholm

Dignitana AB announces that Chief Executive Officer William Cronin will speak at Aktiedagen Stockholm on 19 March 2019 at 15:00 CET.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär